Skip to main content
Premium Trial:

Request an Annual Quote

Pathway, Susan G. Komen Partner on Breast Cancer Education

NEW YORK (GenomeWeb) – Pathway Genomics has partnered with the Susan G. Komen organization to fund breast cancer education and outreach programs in five US cities.

Under the partnership, Pathway will sponsor Susan G. Komen Race for the Cure events in San Diego, Los Angeles, Denver, and Seattle, and provide grants for needy women in Washington, DC, where more women die from breast cancer than in any US city. The new pact builds on a partnership announced by the organizations in June to educate women about available screening options for detecting genetic predisposition to cancer.

Earlier in June, Pathway launched BRCATrue, a next-generation sequencing and PCR test for gauging variations in BRCA1 and BRCA2 genes associated with a heightened risk of hereditary breast and ovarian cancers. The non-invasive saliva-based test is list priced at $1,799. Simultaneous with the test's launch in June, Pathway also introduced the BRCA One for One program, through which the company has pledged to perform a free BRCA test for a woman in need for every "qualified" BRCA test conducted.

When it launched these programs, Pathway indicated that it intended to partner with patient advocacy organizations to educate and reach underserved women who lack access to genetic testing. Pathway has allocated $10 million toward performing free testing through the One for One program for the next two years.

Pathway's BRCA One for One program aligns well with Komen's breast cancer support and education efforts. Last year, for example, Komen funded more than 500,000 screenings for low-income and uninsured women and helped more than 50,000 women pay for treatment, education, and emergency living. Pathway said that it also provides support for Komen's Honoring the Promise event in Washington, DC, to raise funds for area programs and for Komen's annual leadership conference.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.